Case Report

Recovery from Repeated Sudden Hearing Loss in a Patient with Takayasu’s Arteritis Treated with Hyperbaric Oxygen Therapy: The First Report in the Literature

Massimo Ralli,1 Antonio Greco,2 Vincenzo Falasca,2 Giancarlo Altissimi,2 Mario Tombolini,2 Rosaria Turchetta,2 Sara de Fazio,2 Marco de Vincentiis,2 and Giancarlo Cianfrone2

1Department of Oral and Maxillofacial Sciences, Sapienza University of Rome, Rome, Italy
2Department of Sense Organs, Sapienza University of Rome, Rome, Italy

Correspondence should be addressed to Massimo Ralli; massimo.ralli@uniroma1.it

Received 14 June 2017; Accepted 2 August 2017; Published 10 September 2017

Academic Editor: Dimitrios G. Balatsouras

Hearing loss has been rarely reported in Takayasu’s arteritis, may present as Sudden Sensorineural Hearing Loss, and usually responds well to corticosteroid therapy. Hyperbaric Oxygen Therapy is commonly used as a supplementary treatment to corticosteroids for Sudden Sensorineural Hearing Loss. We present the case of a 36-year-old woman with Takayasu’s arteritis who had two episodes of sudden hearing loss involving one ear at a time with an 11-month delay between each episode. During the first episode, the patient was treated with high-dose intramuscular corticosteroids with a temporary improvement of auditory threshold that deteriorated 14 days after cessation of therapy. In the second episode, Hyperbaric Oxygen Therapy was associated with corticosteroids, with improvements in both ears, including the one that was unresponsive in the long term to previous pharmacologic therapy. In this case, Hyperbaric Oxygen Therapy could have acted synergically with corticosteroids playing a role in hearing restoration.

1. Introduction

Takayasu’s arteritis (TA), also known as aortitis syndrome, is a vasculitis more prevalent in women of reproductive age that mainly affects large elastic arteries with symptoms caused by organ ischemia, aneurysm formation, and inflammation [1]. Clinical features usually reflect limb or organ ischemia that follow gradual stenosis of the involved arteries [2, 3].

Hearing loss (HL) has been rarely reported in Takayasu’s arteritis, may present as Sudden Sensorineural Hearing Loss, and usually responds well to corticosteroid therapy. Hyperbaric Oxygen Therapy is commonly used as a supplementary treatment to corticosteroids for Sudden Sensorineural Hearing Loss. We present the case of a 36-year-old woman with Takayasu’s arteritis who had two episodes of sudden hearing loss involving one ear at a time with an 11-month delay between each episode. During the first episode, the patient was treated with high-dose intramuscular corticosteroids with a temporary improvement of auditory threshold that deteriorated 14 days after cessation of therapy. In the second episode, Hyperbaric Oxygen Therapy was associated with corticosteroids, with improvements in both ears, including the one that was unresponsive in the long term to previous pharmacologic therapy. In this case, Hyperbaric Oxygen Therapy could have acted synergically with corticosteroids playing a role in hearing restoration.

2. Case Report

A 36-year-old woman affected by TA was treated in the Otolaryngology Department of the Policlinico Umberto I Hospital, Sapienza University of Rome, following two episodes of sudden hearing loss with continuous low-pitch tinnitus without vertigo and associated neurovegetative symptoms.
Weber test was lateralized to the left at all frequencies.

49.54 dBHL and normal hearing in the left side (Figure 3(a)). Hearing loss in the right ear with an average PTA threshold of 38.18 dBHL; threshold in the right ear was unmodified compared to the exam performed 14 days after cessation of previous treatment (56.09 dB HL) (Figure 3(b)) but deteriorated close to previous level (average threshold in the right ear: 54.09 dB HL) 14 days after cessation of therapy, as shown in Figure 3(c). Hearing remained stable over the following months.

Several months later, in March 2017, the patient was admitted to our Department complaining of a new episode of SSHL which occurred in the left ear. PTA confirmed a new onset SSHL in the left ear, with an average PTA threshold of 38.18 dB HL; threshold in the right ear was unmodified compared to the exam performed 14 days after cessation of previous treatment (56.09 dB HL) (Figure 4(a)). The patient was already undergoing maintenance steroid therapy (0.3 mg/kg methylprednisolone/day). The patient was treated with high-dose intramuscular steroid therapy (betamethasone 8 mg/day for 10 days) accompanied by 16 sessions of HBOT (1/day, 6 days/week) started two days after the SSHL episode. PTA recorded 2 weeks after SSHL onset showed a significant improvement of HL in the left ear (average: 22.72 dB HL) but also in the right ear (average: 30.45 dB HL) (Figure 4(b)). Hearing thresholds in both ears remained stable over the following two months (Figure 4(c)).

3. Discussion

3.1. Takayasu’s Arteritis and Hearing Loss. In this patient, hearing loss presented as SSHL in two episodes involving one ear at a time, with an 11-month delay between each other and with different paths of hearing recovery. The first episode, occurring in the right ear, was treated with corticosteroid therapy only and showed hearing improvement during therapy that deteriorated soon after cessation of the therapy. The second (left ear) was treated with corticosteroid therapy and HBOT; this therapy induced a significant improvement in the affected ear and, interestingly, also in the contralateral side. In addition, hearing thresholds in both ears did not change for a period of two months after completion of the therapy.

There are only a few cases in the literature that reported an association of TA with HL [8–10]. HL in TA may present as SSHL and is usually diagnosed and treated as an idiopathic SSHL. However, HL associated with TA arteritis is often progressive and fluctuates during treatment; it may have a good response to corticosteroid therapy but may also persist despite corticosteroid therapy [11]. A progressive fluctuating bilateral asymmetric SNHL that develops over several weeks to months is a common finding in autoimmune disorders [12, 13].

The etiology of hearing deficits in TA is unknown [14, 15]. A connection with the autoimmune pathophysiology of TA has been hypothesized due to the elevation of serum immune complexes in TA that deposit in the inner ear [14], hypercoagulability in response to the arterial disease [16],
and the good response to anti-inflammatory therapy with corticosteroids. Although TA involves medium and large caliber arteries, Maruyoshi speculated that HL in TA could have a vascular background based on reversible circulatory disturbances due to vasculitis and/or some autoimmune pathogenesis in the inner ear, especially in hair cells [11].

3.2. Effects of Steroid Therapy on Hearing Loss in Takayasu’s Arteritis. Many authors confirmed the beneficial effects of steroid administration on HL in TA; therefore steroids should be used as first-line therapy in this condition [9, 14, 15]. However, steroid therapy must be administered chronically to control TA symptoms; the interruption of steroid treatment has been reported to exacerbate the hearing deficit [15]. Intratympanic injection of steroids may be an alternative treatment to systemic therapy.

One of the first authors to report HL in TA was Kanzaki in 1981, who described a beneficial effect of prednisolone [14]. Murofushi et al. reported a case of a 44-year-old woman with fluctuating sensorineural HL in the high frequencies suffering from TA who was treated with intratympanic injection of dexamethasone at the time of worsening of hearing [17].

Kunihiro et al. reported 5 cases of TA patients with HL in which the degree of hearing loss correlated well with the erythrocyte sedimentation rate. All patients responded well to corticosteroid therapy, supporting the hypothesis that inner ear manifestations of the disease arose from similar mechanisms as those of systemic inflammatory process [9]. In 2005 Maruyoshi et al. reported a case of a 49-year-old woman with TA who experienced sudden hearing loss five years before diagnosis of TA, treated with systemic corticosteroid therapy. After cessation of the therapy, HL worsened. After TA diagnosis, the patient was treated with daily prednisolone (0.3 mg/kg/day) with significant improvement in hearing threshold in the right ear, while no changes were found in the contralateral ear [11].

TA has been reported to be associated with Cogan’s syndrome [18], a rare disorder of unknown origin characterized by inflammatory eye disease (74% of the cases) with interstitial keratitis and vestibulоauditory symptoms [19]. In this case, ocular and vestibular symptoms were never reported despite the long history of TA in the patient; furthermore, auditory involvement is always severe and frequently progresses within several hours or days to total deafness [20]. Therefore, Cogan’s syndrome was ruled out in this case.

3.3. Possible Role of Hyperbaric Oxygen Therapy in Treating Hearing Loss in Takayasu’s Arteritis. In this patient, we found
a significant improvement of hearing threshold in both ears with HBOT performed in conjunction with high-dose corticosteroid therapy after the second episode of SSHL. Interestingly, HBOT induced a rapid increase in hearing threshold in both ears, more marked in the right ear in which hearing significantly decreased 11 months prior to therapy, and had shown to be unresponsive in the long term to steroid therapy performed immediately after HL onset. A possible explanation of this finding could be attributed to the vascular effects of hyperbaric therapy, such as enhancing oxygen, glucose, and adenosine triphosphate delivery to ischemic tissues, and vasodilation. However, the selectivity of TA for medium and large arteries raises questions about effectiveness of such therapy in small vessels such as in the inner ear; our findings could support the involvement of inner ear microcirculation in HL presenting in TA patients.

Although the exclusive role of HBOT in this patient cannot be documented since it has been performed in addition to steroid therapy and no long term follow-up is available, the significant improvement on HL in both sides, including the one in which HL presented over 11 months prior to HBOT, is certainly worth discussion. In this case, HBOT could have worked synergically with steroid therapy and amplified treatment results in the long term.
Figure 4: Pure Tone Audiometry recorded one, 14, and 60 days after onset of sudden hearing loss in the left ear (second episode). (a) Pure Tone Audiometry confirmed hearing loss in the left ear, with an average threshold of 38.18 dB HL; threshold in the right ear was unmodified compared to the exam performed 14 days after cessation of previous treatment (56.09 dB HL); (b) Pure Tone Audiometry recorded 14 days after hearing loss onset showed a significant improvement of hearing loss in the left ear (average: 22.72 dB HL) but also in the right ear (average: 30.45 dB HL); (c) Audiometry 60 days after left sudden hearing loss onset showed no significant differences compared to previous exam, with preserved hearing threshold in both ears.

Current findings certainly require further studies on larger samples; however, they may suggest, when no individual contraindication is present, the use of HBOT even several months after HL onset in patients with a diagnosis of TA.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] R. Serra, L. Butrico, F. Fugetto et al., “Updates in pathophysiology, diagnosis and management of takayasu arteritis,” Annals of Vascular Surgery, vol. 35, pp. 210–225, 2016.

[2] F. Alibaz Oner, S. Z. Aydin, and H. Direskeneli, “Recent Advances in Takayasu’s Arteritis,” European Journal of Rheumatology, vol. 2, no. 1, pp. 24–30, 2014.

[3] G. Keser, H. Direskeneli, and K. Aksu, “Management of Takayasu arteritis: a systematic review,” Rheumatology, vol. 53, no. 5, Article ID ket320, pp. 793–801, 2014.

[4] M. H. Bennett, T. Kertesz, and P. Yeung, “Hyperbaric oxygen for idiopathic sudden sensorineural hearing loss and tinnitus,” Cochrane database of systematic reviews (Online), no. 1, Article ID CD004739, 2007.

[5] M. H. Bennett, T. Kertesz, M. Perleth, P. Yeung, and J. P. Lehmp, “Hyperbaric oxygen for idiopathic sudden sensorineural hearing loss and tinnitus,” Cochrane Database of Systematic Reviews, vol. 10, Article ID CD004739, 2012.
[6] S. Hosokawa, K. Sugiyma, G. Takahashi et al., "Hyperbaric Oxygen Therapy as Adjuvant Treatment for Idiopathic Sudden Sensorineural Hearing Loss after Failure of Systemic Steroids," *Audiology and Neurotology*, vol. 22, no. 1, pp. 9–14, 2017.

[7] W. P. Arend, B. A. Michel, D. A. Bloch et al., "The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis," *Arthritis and Rheumatism*, vol. 33, no. 8, pp. 1129–1134, 1990.

[8] T. J. Siglock and K. H. Brookler, "Sensorineural hearing loss associated with takayasu's disease," *Laryngoscope*, vol. 97, no. 7, pp. 797–800, 1987.

[9] T. Kunihiro, J. Kanzaki, T. O-Uchi, and A. Yoshida, "Steroid-responsive sensorineural hearing loss associated with aortitis syndrome," *ORL*, vol. 52, no. 2, pp. 86–95, 1990.

[10] T. Yasui and T. Yamasoba, "Acute sensorineural hearing loss associated with aortitis syndrome," *Acta Oto-Laryngologica*, vol. 127, no. 559, pp. 29–33, 2007.

[11] H. Maruyoshi, K. Toyama, S. Kojima et al., “Sensorineural hearing loss combined with Takayasu’s arteritis,” *Internal Medicine*, vol. 44, no. 2, pp. 124–128, 2005.

[12] M. J. Ruckenstein, "Autoimmune inner ear disease," *Current Opinion in Otolaryngology & Head and Neck Surgery*, vol. 12, no. 5, pp. 426–430, 2004.

[13] T. Mijovic, A. Zeitouni, and I. Colmegna, "Autoimmune sensorineural hearing loss: the otology-rheumatology interface," *Rheumatology*, vol. 52, no. 5, Article ID kef009, pp. 780–789, 2013.

[14] J. Kanzaki and T. Ouchi, "Steroid-responsive bilateral sensorineural hearing loss and immune complexes," *Archives of Oto-Rhino-Laryngology*, vol. 230, no. 1, pp. 5–9, 1981.

[15] J. Kanzaki, "Immune-mediated sensorineural hearing loss," *Acta Oto-Laryngologica*, vol. 114, no. 514, pp. 70–72, 1994.

[16] I. Loukil, N. Mallouch, F. Hachicha, R. Bhiri, A. Hijazi, and A. Jeddi Blouza, "Ischemic retinopathy in Takayasu disease," *Presse Medicale*, vol. 41, no. 12, pp. e594–e598, 2012.

[17] T. Murofushi, H. Nakahara, A. Sakata, and M. Matsuzaki, "Intratympanic injection of dexamethasone as an alternative treatment of steroid-dependent sensorineural hearing loss associated with aortitis syndrome," *Auris Nasus Larynx*, vol. 34, no. 2, pp. 225–228, 2007.

[18] J. R. Stone, P. Bruneval, and A. Angelini, "Consensus statement on surgical pathology of the aorta from the Society for Cardiovascular Pathology and the Association for European Cardiovascular Pathology: I. Inflammatory diseases," *Cardiovascular Pathology*, vol. 24, no. 5, pp. 267–278, 2015.

[19] G. Migliori, E. Battisti, M. Pari, N. Vitelli, and C. Cingolani, "A shifty diagnosis: Cogan’s syndrome. A case report and review of the literature," *Acta Otorhinolaryngologica Italica*, vol. 29, no. 2, pp. 108–113, 2009.

[20] A. Kessel, Z. Vadasz, and E. Toubi, "Cogan syndrome—pathogenesis, clinical variants and treatment approaches," *Autoimmunity Reviews*, vol. 13, no. 4-5, pp. 351–354, 2014.